Q2 2021 EPS Estimates for Teva Pharmaceutical Industries Limited Cut by Analyst (NYSE:TEVA)

Teva Pharmaceutical Industries Limited (NYSE:TEVA) – Analysts at Truist Securiti reduced their Q2 2021 earnings estimates for shares of Teva Pharmaceutical Industries in a note issued to investors on Wednesday, April 28th. Truist Securiti analyst G. Gilbert now expects that the company will earn $0.55 per share for the quarter, down from their previous estimate of $0.56. Truist Securiti also issued estimates for Teva Pharmaceutical Industries’ Q3 2021 earnings at $0.65 EPS and Q4 2021 earnings at $0.76 EPS.

Other analysts also recently issued research reports about the company. JPMorgan Chase & Co. reissued a “hold” rating and set a $10.00 target price on shares of Teva Pharmaceutical Industries in a research note on Sunday, March 14th. TheStreet upgraded Teva Pharmaceutical Industries from a “d+” rating to a “c-” rating in a report on Monday, April 5th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and four have issued a buy rating to the stock. Teva Pharmaceutical Industries presently has a consensus rating of “Hold” and a consensus target price of $11.98.

Shares of TEVA opened at $10.81 on Monday. The business’s 50 day moving average is $11.02 and its 200 day moving average is $10.61. The company has a market capitalization of $11.81 billion, a PE ratio of -2.94, a price-to-earnings-growth ratio of 0.87 and a beta of 1.49. Teva Pharmaceutical Industries has a 12-month low of $8.44 and a 12-month high of $13.30. The company has a current ratio of 1.00, a quick ratio of 0.63 and a debt-to-equity ratio of 2.22.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Wednesday, April 28th. The company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.55 by $0.08. The company had revenue of $3.98 billion for the quarter, compared to the consensus estimate of $4.04 billion. Teva Pharmaceutical Industries had a positive return on equity of 19.32% and a negative net margin of 24.17%. The firm’s quarterly revenue was down 8.6% on a year-over-year basis. During the same quarter last year, the company earned $0.76 EPS.

Institutional investors have recently made changes to their positions in the company. Focused Wealth Management Inc boosted its holdings in Teva Pharmaceutical Industries by 3.9% during the 1st quarter. Focused Wealth Management Inc now owns 33,567 shares of the company’s stock valued at $387,000 after acquiring an additional 1,268 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Teva Pharmaceutical Industries by 14.9% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 286,026 shares of the company’s stock valued at $3,301,000 after acquiring an additional 37,046 shares during the period. Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet LTD boosted its holdings in Teva Pharmaceutical Industries by 126.6% during the 1st quarter. Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet LTD now owns 380,294 shares of the company’s stock valued at $4,389,000 after acquiring an additional 212,433 shares during the period. Raymond James Trust N.A. boosted its holdings in Teva Pharmaceutical Industries by 5.2% during the 1st quarter. Raymond James Trust N.A. now owns 49,793 shares of the company’s stock valued at $575,000 after acquiring an additional 2,481 shares during the period. Finally, Centaurus Financial Inc. boosted its holdings in Teva Pharmaceutical Industries by 58.9% during the 1st quarter. Centaurus Financial Inc. now owns 16,504 shares of the company’s stock valued at $190,000 after acquiring an additional 6,115 shares during the period. Hedge funds and other institutional investors own 51.20% of the company’s stock.

In other news, insider Mark Sabag sold 127,244 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Tuesday, March 16th. The stock was sold at an average price of $11.22, for a total value of $1,427,677.68. Following the completion of the transaction, the insider now owns 20,598 shares in the company, valued at approximately $231,109.56. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.56% of the stock is currently owned by insiders.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Read More: The limitations of an equal weight rating

Earnings History and Estimates for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit